Balchem Co. Forecasted to Post Q2 2025 Earnings of $1.04 Per Share (NASDAQ:BCPC)

Balchem Co. (NASDAQ:BCPC) – Stock analysts at HC Wainwright issued their Q2 2025 earnings estimates for shares of Balchem in a note issued to investors on Monday, May 6th. HC Wainwright analyst R. Selvaraju anticipates that the basic materials company will post earnings of $1.04 per share for the quarter. HC Wainwright currently has a “Buy” rating and a $170.00 price target on the stock. The consensus estimate for Balchem’s current full-year earnings is $4.10 per share. HC Wainwright also issued estimates for Balchem’s Q4 2025 earnings at $1.12 EPS.

Balchem (NASDAQ:BCPC) last announced its quarterly earnings data on Friday, February 16th. The basic materials company reported $0.95 EPS for the quarter, beating analysts’ consensus estimates of $0.93 by $0.02. The company had revenue of $228.70 million during the quarter, compared to the consensus estimate of $234.66 million. Balchem had a return on equity of 11.03% and a net margin of 12.35%. The company’s quarterly revenue was down 1.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.66 EPS.

Separately, StockNews.com cut shares of Balchem from a “buy” rating to a “hold” rating in a report on Thursday, April 25th.

Balchem Trading Down 1.4 %

NASDAQ:BCPC opened at $153.28 on Wednesday. The stock has a fifty day simple moving average of $150.98 and a 200 day simple moving average of $141.30. The company has a quick ratio of 1.72, a current ratio of 2.61 and a debt-to-equity ratio of 0.31. The firm has a market capitalization of $4.97 billion, a price-to-earnings ratio of 43.30, a price-to-earnings-growth ratio of 3.33 and a beta of 0.72. Balchem has a 1-year low of $110.74 and a 1-year high of $159.52.

Hedge Funds Weigh In On Balchem

Hedge funds have recently added to or reduced their stakes in the company. Signaturefd LLC grew its position in Balchem by 123.0% in the fourth quarter. Signaturefd LLC now owns 165 shares of the basic materials company’s stock worth $25,000 after acquiring an additional 91 shares in the last quarter. Principal Securities Inc. acquired a new position in Balchem during the fourth quarter worth $28,000. Operose Advisors LLC bought a new position in Balchem during the third quarter valued at about $31,000. GAMMA Investing LLC acquired a new stake in shares of Balchem in the fourth quarter worth about $56,000. Finally, YHB Investment Advisors Inc. acquired a new stake in shares of Balchem in the first quarter worth about $69,000. Institutional investors and hedge funds own 87.91% of the company’s stock.

Insider Transactions at Balchem

In other Balchem news, CAO William A. Backus sold 15,000 shares of Balchem stock in a transaction dated Wednesday, February 21st. The stock was sold at an average price of $154.73, for a total transaction of $2,320,950.00. Following the transaction, the chief accounting officer now owns 12,914 shares of the company’s stock, valued at approximately $1,998,183.22. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, SVP Michael Robert Sestrick sold 11,100 shares of Balchem stock in a transaction on Wednesday, February 21st. The stock was sold at an average price of $153.21, for a total transaction of $1,700,631.00. Following the completion of the sale, the senior vice president now owns 6,736 shares of the company’s stock, valued at $1,032,022.56. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CAO William A. Backus sold 15,000 shares of the company’s stock in a transaction dated Wednesday, February 21st. The stock was sold at an average price of $154.73, for a total value of $2,320,950.00. Following the completion of the transaction, the chief accounting officer now directly owns 12,914 shares in the company, valued at $1,998,183.22. The disclosure for this sale can be found here. Insiders sold a total of 76,630 shares of company stock valued at $11,843,249 over the last quarter. Company insiders own 1.77% of the company’s stock.

Balchem Company Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.